Sponsored by:

Molecular Imaging

Juniper secures FDA 'breakthrough' nod for hypoxia PET tracer
By AuntMinnie.com staff writers
JBS-003, licensed from Memorial Sloan Kettering Cancer Center, identifies tumor hypoxia, a marker of radioresistance.
September 3, 2026
Throat Cancer
Telix completes enrollment in BiPASS study
By AuntMinnie.com staff writers
In earlier studies, combining Ga-68 PSMA-PET with MRI reduced unnecessary biopsies by nearly 50 percent.
September 2, 2026
Prostate Imaging
Ionetix begins shipping At-211 in North America
By AuntMinnie.com staff writers
Alpha emitters like At-211 deliver high-energy radiation over a very short range.
September 2, 2026
Nuclear Medicine
SPECT/CT access unequal across U.S.
By Will Morton
At the state level, California, Texas, and Florida had the highest number of facilities in absolute terms.
September 1, 2026
Shutterstock 2028051956 (1)
Bayer's PET agent meets endpoints in phase III cardiac amyloidosis study
By Will Morton
Overall sensitivity was 94% (95% CI, 85% to 98%) and specificity was 86% (95% CI, 77% to 92%).
August 31, 2026
This figure shows fused I-124 evuzamitide positron emission tomography (PET)/computed tomography (CT) images from patients without amyloidosis and from patients with ATTR cardiac amyloidosis, early ATTR cardiac amyloidosis, light chain cardiac amyloidosis, gelsolin-mediated amyloidosis, and systemic organ amyloid. The columns represent radiological transaxial, sagittal, and coronal views except for the last row middle and far right columns, which are coronal projections. The blue asterisks represent physiological activity (tracer activity in the stomach and esophagus). The arrowheads represent pathological uptake. Note the small amount of cardiac uptake in the basal septum and the basal lateral walls (likely early ATTR cardiac amyloidosis), splenic uptake and pleural uptake in light chain amyloidosis, and cardiac and kidney uptake in gelsolin-mediated amyloidosis. The bright yellow color represents more tracer uptake.
PET outperforms CT in ovarian cancer
By Will Morton
Peritoneal carcinomatosis in ovarian cancer is cancer that has spread from the ovaries to the peritoneum.
August 28, 2026
Comparison of contrast-enhanced CT (ceCT) and FAPI-PET in detecting peritoneal carcinomatosis in patient with advanced ovarian carcinoma. (A) ceCT shows subtle peritoneal thickening that is difficult to delineate. (B) Maximum-intensity-projection image demonstrating diffuse intense FAPI uptake corresponding to extensive peritoneal carcinomatosis. (C) FAPI-PET shows intense uptake corresponding with peritoneal carcinomatosis, with improved lesion conspicuity over ceCT.
PET/CT outperforms MRI after focal therapy for prostate cancer
By Will Morton
No accurate noninvasive method has been validated to evaluate treatment response after focal therapy.
August 20, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
Cortechs.ai wins FDA clearance for NeuroQuant PET
By AuntMinnie.com staff writers
The software offers automated quantification for amyloid PET imaging in Alzheimer's disease and other neurological conditions.
August 19, 2026
A Ibrain
Norroy secures FDA breakthrough therapy, fast track status for PET imaging agent
By AuntMinnie.com staff writers
Norroy said Ga-68 NYM096 is the first China-originated radiopharmaceutical to receive FDA breakthrough therapy designation.
August 19, 2026
Kidney
IU Health launches theranostics center
By AuntMinnie.com staff writers
The center is supported by a $40 million commitment.
August 19, 2026
Nuclearmedicine
New immuno-PET tracer shows promise in lung cancer
By Will Morton
Molecular imaging can provide whole-body visualization and quantitative assessment of PD-L1 expression.
August 18, 2026
(A) Ga-68 NK224 PET/CT maximum intensity projection image (left), axial PET/CT images (center), and axial CT images (right) in a 43-year-old female participant with lung adenocarcinoma show lesions in the right cerebellum (blue arrow), right frontal lobe (red arrow), and sternum (green arrow) with low, intermediate, and high tracer uptake, respectively. Photomicrographs (scale bar, 100 μm) with hematoxylin-eosin (H&E) staining (center bottom) and programmed death ligand 1 (PD-L1) immunohistochemical (IHC) staining (right bottom) show high PD-L1 expression in the sternal lesion (tumor proportion score ≥ 50%).
Lantheus wins FDA approval for tau PET imaging agent
By AuntMinnie.com staff writers
Tauklarify, previously known as MK-6240, has been approved for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer's disease.
August 14, 2026
Approved Stamp 400
Page 1 of 634
Next Page